REVISTA ESPANOLA DE CARDIOLOGIA

[Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management]
Barreiro-Pérez M, Pastor Pueyo P, Raposeiras-Roubín S, Montero Corominas D, Uribarri A, Eiros Bachiller R, Rozado Castaño J, García-Cuenllas Álvarez L, Serratosa Fernández L, Domínguez F and Pascual Figal D
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vaccination programs, and the appearance of new information on myocarditis in these contexts, there is a need to condense the knowledge acquired since the start of the pandemic. To meet this need, this document was drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS). The document aims to address the diagnosis and treatment of cases of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.
[Cardiopulmonary exercise test in patients with post SARS-CoV-2 sequelae: need to create a multicenter working group. Response]
Ramírez-Vélez R, García-Alonso N, Oteiza J and Izquierdo M
[Cardiopulmonary exercise test in patients with post SARS-CoV-2 sequelae: need to create a multicenter working group]
Vannini L, Quijada-Fumero A, Laynez-Carnicero A and Hernández Afonso JS
[Third-degree atrioventricular block associated with the SARS-CoV-2 mRNA vaccine]
Pons-Riverola A, Mañas P, Claver E, Meroño O, Comín-Colet J and Anguera I
[Early remote monitoring of pacemaker devices and benefits of this paradigm shift. The FAST REMOTE study]
Valverde André I, González Vasserot M, Gonzalez Chana B, González Matos C, Villagraz Tecedor L, García Fernández FJ and
[Ventilatory efficiency in response to maximal exercise in persistent COVID-19 syndrome patients: a cross-sectional study]
Ramírez-Vélez R, García-Alonso N, Legarra-Gorgoñón G, Oscoz-Ochandorena S, Oteiza J and Izquierdo M
[Spanish catheter ablation registry. 21st official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2021)]
Anguera I, Cano Pérez Ó, Bazán V and
The results of the 2021 Spanish catheter ablation registry are presented.
[Environment and cardiovascular health: causes, consequences and opportunities in prevention and treatment]
Bañeras J, Iglesies-Grau J, Téllez-Plaza M, Arrarte V, Báez-Ferrer N, Benito B, Campuzano Ruiz R, Cecconi A, Domínguez-Rodríguez A, Rodríguez-Sinovas A, Ujueta F, Vozzi C, Lamas GA and Navas-Acién A
The environment is a strong determinant of cardiovascular health. Environmental cardiology studies the contribution of environmental exposures with the aim of minimizing the harmful influences of pollution and promoting cardiovascular health through specific preventive or therapeutic strategies. The present review focuses on particulate matter and metals, which are the pollutants with the strongest level of scientific evidence, and includes possible interventions. Legislation, mitigation and control of pollutants in air, water and food, as well as environmental policies for heart-healthy spaces, are key measures for cardiovascular health. Individual strategies include the chelation of divalent metals such as lead and cadmium, metals that can only be removed from the body via chelation. The TACT (Trial to Assess Chelation Therapy, NCT00044213) clinical trial demonstrated cardiovascular benefit in patients with a previous myocardial infarction, especially in those with diabetes. Currently, the TACT2 trial (NCT02733185) is replicating the TACT results in people with diabetes. Data from the United States and Argentina have also shown the potential usefulness of chelation in severe peripheral arterial disease. More research and action in environmental cardiology could substantially help to improve the prevention and treatment of cardiovascular disease.
[Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers]
Eiros R, Barreiro-Pérez M, Martín-García A, Almeida J, Villacorta E, Pérez-Pons A, Merchán S, Torres-Valle A, Sánchez-Pablo C, González-Calle D, Pérez-Escurza O, Toranzo I, Díaz-Peláez E, Fuentes-Herrero B, Macías-Álvarez L, Oliva-Ariza G, Lecrevisse Q, Fluxa R, Bravo-Grande JL, Orfao A, Sánchez PL and
The cardiac sequelae of SARS-CoV-2 infection are still poorly documented. We conducted a cross-sectional study in healthcare workers to report evidence of pericardial and myocardial involvement after SARS-CoV-2 infection.
[Acute myocarditis after a third dose of the BNT162b2 COVID-19 vaccine]
Fosch X, Serra J, Torres PL, Preda L, González R and Mojer F
[An adolescent girl with severe biventricular dysfunction and pediatric inflammatory multisystem syndrome after COVID-19]
Jiménez Martínez C, Heras Hernando VM, Gaite de Vicente P, Godoy Tundidor MV, Afonso Rivero D and Gabán Díez Á
[Echocardiography in the acute phase of COVID-19 infection: impact on management and prognosis]
González-Del-Hoyo M, Servato L, Ródenas E, Bañeras J, Ferreira-González I and Rodríguez-Palomares J
[Long COVID-19 and microvascular disease-related angina]
Vallejo Camazón N, Teis A, Martínez Membrive MJ, Llibre C, Bayés-Genís A and Mateu L
[Rare cases of myocarditis after COVID-19 vaccination: searching for diagnosis, type, treatment and prevention]
Kounis NG, Mplani V, Koniari I and Plotas P
[Brugada phenocopy in a child with pediatric inflammatory multisystemic syndrome caused by SARS-CoV-2]
Santiago-Cortés R, Clavero-Adell M, Palanca-Arias D, Jiménez-Montañés L, López-Ramón M and Ayerza-Casas A
[Relevance of myocardial injury biomarkers to the prognosis of COVID-19 patients]
Alcaide E, Álvarez Bota L and Salas R
[Cardiovascular events after COVID-19 hospitalization: long-term follow-up]
Negreira-Caamaño M, Martínez-Del Río J, Águila-Gordo D, Mateo-Gómez C, Soto-Pérez M and Piqueras-Flores J
[Epicardial adipose tissue attenuation in admitted patients with COVID-19]
Sevilla T, Aparisi-Sanz Á, Aristizábal-Duque C, Gómez-Salvador I, Baladrón C and San Román A
[Relevance of myocardial injury biomarkers to the prognosis of COVID-19 patients. Response]
Calvo-Fernández A, Marrugat J and Vaquerizo B
[Spanish Catheter Ablation Registry. 20th Official Report of the Heart Rhythm Association of the Spanish Society of Cardiology (2020)]
Cózar León R, Anguera Camós I, Cano Pérez Ó and
This article reports the results of the 2020 Spanish Catheter Ablation Registry, a year marked by the SARS-CoV-2 pandemic.
[Mortality risk in COVID-19 patients with right bundle branch block]
Zuin M, Rigatelli G, Roncon L and Zuliani G